Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).
Quantum BioPharma has appointed Kevin Malone as an advisor to its Board of Directors, leveraging his extensive experience in combating stock manipulation and naked short selling. This strategic move is expected to enhance Quantum’s efforts in fighting market corruption, aligning with Malone’s commitment to financial integrity and his interest in Quantum’s mission to develop treatments for multiple sclerosis.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Their lead compound, Lucid-MS, is aimed at treating multiple sclerosis by preventing and reversing myelin degradation. The company also has a strategic investment portfolio and retains a significant stake in Celly Nutrition, which markets the OTC product unbuzzd™.
YTD Price Performance: 52.94%
Average Trading Volume: 2,820,994
Technical Sentiment Signal: Buy
Current Market Cap: $14.13M
See more data about QNTM stock on TipRanks’ Stock Analysis page.